Help is a sufficiently vague term that your proposed question about Teva’s outside help is not especially helpful for investors, IMO. What I’m laying on the table for consideration is the possibility that Teva may have gotten its entire Lovenox drug candidate—hook, line, and sinker—from a third party.
Market Data 
Markets 
AI
